Increased Blood Retinol Levels Are Associated With a Reduced Risk of TIA or Stroke in an Adult Population: Lifestyle Factors- and CVDs-Stratified Analysis

Linjuan Guo¹†, Ying Huang¹†, Rong Wan², Yang Shen² and Kui Hong¹,²*
¹ Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, China, ² Jiangxi Key Laboratory of Molecular Medicine, Nanchang, China

Background: Data on the existing evidence for the association between blood retinol and transient ischemic attack (TIA)/stroke risk are limited, and the results are inconclusive. This study aimed to further assess the associations between the blood retinol levels and the risk of TIA/stroke after controlling the lifestyle factors and age-related confounders.

Methods: The cross-sectional data from 1,113 individuals (aged 34–84 years old) were obtained from the Midlife in the United States (MIDUS) study. The multivariable analyses were performed to investigate the association of blood retinol levels with ever and currently TIA/stroke.

Results: There was an inverse association between the blood retinol levels and the risk of ever TIA or stroke (for per 1 µmol/L adjusted odds ration [OR]: 0.93; 95% CI: 0.89–0.97; for per 1-SD adjusted OR: 0.89; 95% CI: 0.83–0.96) and currently diagnosed TIA or stroke (for per 1 µmol/L adjusted OR: 0.91; 95% CI: 0.87–0.96; for per 1-SD adjusted OR: 0.84; 95% CI: 0.80–0.91) after controlling the lifestyle factors and age-related confounders. The significance of these associations was maintained after a sensitivity analysis and involving “ever chronic respiratory diseases” as a covariate. Moreover, the stratified analyses suggested that the inverse associations could be affected by overweight [body mass index (BMI) ≥ 28, kg/m²], hypertension, and diabetes.

Conclusions: A significant inverse association between blood retinol and the risk of TIA or stroke was found. This inverse association did not change even after adjustment for many potential confounders. Moreover, the potential protective effect of retinol on TIA/stroke could be blunted by overweight [BMI ≥ 28, kg/m²], hypertension, and diabetes.

Keywords: blood retinol, stroke, transient ischemic attack, lifestyle factors, cardiovascular diseases
INTRODUCTION

A transient ischemic attack (TIA) or stroke is a global public health problem that leads to the second leading cause of death (1). However, to date, there are few practical measures to prevent the TIA/stroke. The knowledge of risk factors is an essential step in predicting and further preventing the TIA/stroke. The existing evidence has suggested that the risk factors for TIA/stroke mainly include obesity, lack of physical exercise, hyperlipidemia, smoking, drinking, hypertension, diabetes, heart disease, or others (2). Importantly, in the recent years, the effect of nutrients on the TIA/stroke risk has become the focus of scientific discussion. The guidelines of the American Heart Association (AHA) and American Stroke Association (ASA) recommend that the diets low in saturated fats and salt, and rich in fiber, fruits, and vegetables can effectively reduce the occurrence of TIA/stroke (3).

Blood retinol is a lipid-soluble micronutrient involved in the processes of vision, cell differentiation and proliferation, and immune system regulation (4). In addition, the emerging evidence suggests that retinol has an important inhibitory effect on thrombosis and may also participate in an endothelial function by regulating the nitric oxide pathway (5, 6). A study found that blood retinol can regulate the chronic inflammation and stabilize plaque (7). It is well known that the chronic inflammation and plaque formation are the critical processes in developing atherosclerosis and TIA/stroke. However, data on the association between blood retinol and TIA/stroke risk were limited in the prospective research, and the results were inconclusive (8, 9). More importantly, possible modifiers that impact the relationship between blood retinol and the risk of TIA/stroke are ambiguous.

To our knowledge, few previous studies have comprehensively examined the relationship between blood retinol and the risk of TIA/stroke. The Midlife in the United States (MIDUS) study, a large population-based cohort study of adult individuals (aged 34–84 years) that includes detailed information on the levels of blood nutrients, incidence of cardiovascular diseases (CVDs), and potential confounders, such as the lifestyle factors and age-related confounders. Hence, this study aimed to analyze the impact of blood retinol on TIA/stroke and identify the modifying factors of this impact.

METHODS

This study contains 1,113 subjects from the MIDUS II study, which is a 9-year follow-up of the MIDUS I cohort from 2004 to 2006, such as the demographic, behavioral, and social factors of an adult American population (10). The well-trained staff evaluated a self-administered survey of a wide array of behavioral, social, and psychological factors, and conducted the collection of biomarker project and data during a 2-day visit to the Clinical Research Center (CRC) at the University of California-Los Angeles, Wisconsin, or Georgetown. The respondents completed a list of chronic diseases and asked if they had experienced or been diagnosed with a list of chronic health conditions in the past 12 months, such as stroke/TIA. Blood data was collected from November 2021 | Volume 8 | Article 744611

STATISTICAL ANALYSIS

In this study, SPSS 26.0 (IBM, NY, USA) was used to perform all the analyses. All continuous variables were normally distributed, we represented them by using the median (interquartile range [IQR]) and standardized them by using the Z-score. Then, a multivariate logistic regression analysis was performed. The significance levels were corrected in each model to account for the relationships among the blood retinol levels and ever TIA/stroke and currently diagnosed TIA/stroke, respectively. No adjustment was made in a Crude Model. In Model 1, the blood retinol levels were regressed on both ever TIA/stroke and currently diagnosed TIA/stroke after adjusting for age, gender, and marital status. In Model 2, hemoglobin A1c %, HOMA-IR, fasting glucose levels, fasting insulin levels, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, creatinine, and CRP were further adjusted. The categorical variables were defined as n (%). The subjects with missing data for specific variables were removed from the analysis.

In addition, we then used “chronic respiratory diseases (asthma and emphysema/COPD)” as a covariate for sensitivity analysis to further clarify the impact on blood retinol and its relationship with TIA/stroke. Finally, we performed the stratified analyses using the covariates, such as “overweight [body mass index (BMI) ≥ 28, kg/m²],” “current smoking,” “number of years of drinking (≥6),” “exercise frequency ≥3/week,” “heart disease,” “hypertension,” and “diabetes”. These stratified variables were used to examine whether the lifestyle factors and CVDs affect the association between the blood retinol levels and TIA/stroke. A P-value ≤ 0.05 was considered statistically significant.

RESULTS

Characteristics of the Participants Stratified by Using the Blood Retinol Levels (N = 1,113)

Due to the lack of complete data for 142 participants, data for the remaining 113 participants were included in the
study and further analyzed. Table 1 lists the characteristics of all the included individuals. The median blood retinol of this cohort study was 1.66 µmol/L. Based on the median blood retinol level, we divided the entire study cohort into two groups (Retinol <1.66 and ≥1.66 µmol/L). Comparison of the effect factors between the two groups, there were significant differences in BMI, current smoking status, number of drinking years, frequency of exercises ≥3/week, currently diagnosed TIA/stroke, and ever TIA/stroke, while there were no significant differences in age, gender, and marital status married. In terms of the CVDs history (heart disease, hypertension, and diabetes), individuals with the blood retinol levels below the median were more common than those with the blood retinol levels at or above the median. For the chronic respiratory diseases, emphysema/COPD was more prevalent in the individuals with lower-level blood retinol. Moreover, hemoglobin A1c, HOMA-IR, fasting glucose levels, fasting insulin levels, total cholesterol, LDL cholesterol, CRP were lower, while the HDL cholesterol was higher in the individuals with the higher blood retinol levels. There were no significant
### TABLE 1 | Characteristics of participants stratified by blood retinol levels (N = 1,113).

| Variables                        | Total participants (N = 1,113) | Retinol < 1.66 umol/L (N = 557) | Retinol ≥ 1.66 umol/L (N = 556) | P-value |
|----------------------------------|--------------------------------|---------------------------------|---------------------------------|---------|
| Age (years)                      | 53.0 (45.0–62.0)               | 52.5 (44.6–61.3)               | 53.2 (45.6–62.4)               | 0.112   |
| Gender (male), n (%)             | 470 (43.2)                     | 251 (45.1)                     | 219 (39.4)                     | 0.051   |
| Currently married, n (%)         | 688 (61.8)                     | 354 (63.6)                     | 334 (60.1)                     | 0.392   |
| BMI (kg/m²)                      | 28.5 (25.2–32.9)               | 30.7 (27.3–35.2)               | 27.1 (22.8–30.5)               | <0.001  |
| Current smoker, n (%)            | 168 (15.1)                     | 106 (19.4)                     | 60 (10.8)                      | <0.001  |
| Number of drinking years         | 7.0 (3.0–23.0)                 | 8.0 (4.0–24.0)                 | 5.0 (2.0–21.0)                 | 0.021   |
| Frequency of exercises ≥ 3/week, n (%) | 821 (73.8)               | 391 (70.2)                     | 430 (77.3)                     | 0.010   |
| Currently diagnosed TIA or stroke, n (%) | 54 (4.9)                     | 38 (6.8)                       | 16 (2.9)                       | <0.001  |
| Ever TIA /stroke, n (%)          | 31 (2.7)                       | 20 (3.5)                       | 11 (2.0)                       | 0.002   |

| CVDs history                     |                                |                                |                                |         |
|----------------------------------|                                |                                |                                |         |
| Heart disease, n (%)             | 112 (10.1)                     | 75 (13.5)                      | 37 (6.7)                       | 0.011   |
| Hypertension, n (%)              | 422 (37.9)                     | 265 (47.6)                     | 157 (28.2)                     | <0.001  |
| Diabetes, n (%)                  | 102 (9.2)                      | 65 (11.7)                      | 37 (6.7)                       | 0.026   |

| Ever chronic respiratory diseases|                                |                                |                                |         |
|----------------------------------|                                |                                |                                |         |
| Asthma, n (%)                    | 129 (11.6)                     | 71 (12.7)                      | 58 (10.4)                      | 0.267   |
| Emphysema/COPD, n (%)            | 39 (3.5)                       | 31 (5.6)                       | 8 (1.4)                        | 0.002   |

| Blood analysis                   |                                |                                |                                |         |
|----------------------------------|                                |                                |                                |         |
| Hemoglobin A1c %                 | 5.7 (5.3–6.1)                  | 6.2 (5.4–7.3)                  | 5.3 (5.0–6.5)                  | 0.018   |
| HOMA-IR                          | 2.4 (1.5–4.4)                  | 2.6 (1.7–4.8)                  | 2.1 (1.2–4.1)                  | 0.020   |
| Fasting glucose levels mg/Dl     | 95.0 (92.0–108.0)              | 98.0 (94.0–112.0)              | 92.0 (89.0–101.0)              | 0.012   |
| Fasting insulin levels uIU/mL    | 11.0 (5.0–16.0)                | 13.0 (6.0–18.0)                | 9.0 (3.0–15.0)                 | 0.017   |
| Total Cholesterol (mg/dL)        | 182.7 (162.1–219.3)            | 189.5 (186.3–224.8)            | 180.1 (163.3–213.5)            | 0.004   |
| Triglycerides (mg/dL)            | 105.3 (76.3–154.7)             | 105.9 (76.6–156.3)             | 105.1 (75.8–153.8)             | 0.065   |
| HDL Cholesterol (mg/dL)          | 54.3 (44.6–67.2)               | 52.6 (42.7–63.8)               | 55.1 (45.3–88.5)               | 0.025   |
| LDL Cholesterol (mg/dL)          | 124.8 (81.6–128.8)             | 135.6 (87.9–148.6)             | 116.7 (79.6–119.3)             | 0.003   |
| Creatinine (mg/dL)               | 0.85 (0.72–1.46)               | 0.91 (0.73–1.59)               | 0.83 (0.70–1.35)               | 0.071   |
| C-reactive protein (ug/mL)       | 1.34 (0.62–3.36)               | 1.81 (0.76–3.99)               | 1.27 (0.57–3.2)                | 0.013   |

M (IQR) for non-normally distributed variables, and n (%) for categoric variables.

**BMI**, Body mass index; TIA, transient ischemic attack; CVDs, Cardiovascular diseases; COPD, chronic obstructive pulmonary disease; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; CRP, C-reactive protein.

### TABLE 2 | Multivariate logistic regression analysis for association between blood retinol levels and TIA /stroke (N = 1,113).

| Blood retinol (umol/L) | Ever TIA /stroke | Currently diagnosed TIA /stroke |
|------------------------|------------------|---------------------------------|
|                        | OR               | 95% CI                          | P-value |
|                        | OR               | 95% CI                          | P-value |
| **Crude**              |                  |                                  |         |
| Continuous, per 1umol/L increment | 0.90 | 0.84–0.95 | 0.003 | 0.87 | 0.79–0.92 | <0.001 |
| Per 1-SD increase      | 0.83 | 0.75–0.90 | <0.001 | 0.80 | 0.70–0.86 | <0.001 |
| **Model 1**            |                  |                                  |         |
| Continuous, per 1umol/L increment | 0.91 | 0.86–0.96 | 0.012 | 0.90 | 0.85–0.94 | <0.001 |
| Per 1-SD increase      | 0.85 | 0.77–0.91 | <0.001 | 0.82 | 0.74–0.90 | <0.001 |
| **Model 2**            |                  |                                  |         |
| Continuous, per 1umol/L increment | 0.93 | 0.89–0.97 | 0.024 | 0.91 | 0.87–0.96 | <0.001 |
| Per 1-SD increase      | 0.89 | 0.83–0.96 | 0.002 | 0.84 | 0.80–0.91 | <0.001 |

**Crude:** Adjusted for no.

**Model 1:** Adjusted for age, gender and marital status.

**Model 2:** Adjusted for age, gender, marital status, blood analysis including hemoglobin A1c %, HOMA-IR, fasting glucose levels, fasting insulin levels, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, creatinine and C-reactive protein.

TIA, transient ischemic attack; HOMA-IR, homeostasis model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein.
differences in the triglyceride and creatinine levels between the two groups.

**Increased Blood Retinol Levels Were Associated With a Reduced Risk of TIA/Stroke by Using the Multivariate Logistic Regression Analysis**

The results of the multivariate logistic regression analysis for the association between the blood retinol levels, and ever and currently diagnosed TIA/stroke are shown in Table 2. In the Crude model (unadjusted), with the increment of blood retinol per 1 µmol/L, the incidence of ever TIA/stroke decreased 10% (odds ratio [OR]: 0.90; 95% CI: 0.84–0.95) and currently diagnosed TIA/stroke decreased 13% (OR: 0.87; 95% CI: 0.79–0.92). Similarly, with the increment of blood retinol per 1-SD increase, the incidence of ever TIA/stroke decreased 17% (OR: 0.83; 95% CI: 0.75–0.90), and currently diagnosed TIA/stroke decreased 20% (OR: 0.80; 95% CI: 0.70–0.86). When adjusted for model 1 (adjustment for the confounding factors potentially associated with TIA or stroke), as the blood retinol increased per 1 µmol/L, the risk of ever TIA/stroke was reduced by 9% (OR: 0.91; 95% CI: 0.86–0.96) and currently diagnosed TIA/stroke was reduced by 10% (OR: 0.90; 95% CI: 0.85–0.94). Likewise, with the blood retinol increased every 1-SD, the risk of ever TIA/stroke was reduced by 15% (OR: 0.85; 95% CI: 0.77–0.91) and currently diagnosed TIA/stroke was reduced by 18% (OR: 0.82; 95% CI: 0.74–0.90). In model 2, with the increment of blood retinol per 1 µmol/L, the incidence of ever TIA/stroke decreased by 7% (OR: 0.93; 95% CI: 0.89–0.97), and currently diagnosed TIA/stroke decreased by 9% (OR: 0.91; 95% CI: 0.87–0.96). The incidence of ever had TIA/stroke decreased by 11% (OR: 0.89; 95% CI: 0.83–0.96) and currently diagnosed TIA or stroke decreased by 16% (OR: 0.84; 95% CI: 0.80–0.91) when the blood retinol increased per 1-SD.

**Increased Blood Retinol Levels Contributed to a Reduced Risk of TIA/Stroke by Using the Sensitivity Analysis**

The sensitivity analyses (Table 3) showed that the ORs were little changed by further adjustment for "ever chronic respiratory diseases" in the Crude Model, as well as in the model 1 and model 2 (all P < 0.05). These results further suggested that the significant and independent associations between the blood retinol levels and ever TIA/stroke and currently diagnosed TIA/stroke.

We additionally performed the stratified analyses to assess the effect of blood retinol (per 1 µmol/L and 1-SD increment) on ever TIA/stroke and currently diagnosed TIA/stroke by adding several factors of lifestyle and CVDs as a covariate, respectively (Table 4). Our results suggested that with the blood retinol increase by 1 µmol/L or 1-SD, the risk of ever TIA/stroke and currently diagnosed stroke/TIA were still decreased in the individuals with no-overweight, no-hypertension, and no-diabetes (all P < 0.05), but not decreased in the individuals with the three covariates (all P > 0.05). However, our results showed that the association between the blood retinol and TIA/stroke were not affected by the current smoking status, number of drinking years, frequency of exercises ≥3/week, and heart disease. We first found that overweight, hypertension, and diabetes were modifiers that affect the association between blood retinol and ever TIA/stroke and currently diagnosed stroke/TIA.

**DISCUSSION**

We found that the increased blood retinol levels were associated with a reduced risk of TIA/stroke. This dependent association did change little after the adjustments for many lifestyle factors and age-related confounders. The potential protective effect of retinol on TIA/stroke can be attenuated by overweight, hypertension, and diabetes.
### TABLE 4 | Stratified analysis for association between blood retinol levels and TIA/stroke using multivariate logistic regression models (N = 1,113).

| Blood retinol (umol/L)         | Ever TIA/stroke | Currently diagnosed TIA/stroke |
|-------------------------------|-----------------|-------------------------------|
|                               | OR   | 95% CI   | P-value  | OR   | 95% CI   | P-value  |
| **BMI (≥28, kg/m²)**          |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.97 | 0.92–1.22 | 0.235    | 0.94 | 0.90–1.16 | 0.093    |
| Per 1-SD increase             | 0.95 | 0.90–1.20 | 0.194    | 0.93 | 0.88–1.14 | 0.089    |
| **BMI (<28, kg/m²)**          |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.69 | 0.48–0.85 | 0.007    | 0.61 | 0.42–0.80 | <0.001   |
| Per 1-SD increase             | 0.62 | 0.44–0.83 | 0.001    | 0.55 | 0.38–0.72 | <0.001   |
| **Current smoking (yes)**     |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.94 | 0.89–0.99 | 0.029    | 0.92 | 0.88–0.94 | 0.003    |
| Per 1-SD increase             | 0.85 | 0.80–0.92 | 0.010    | 0.82 | 0.82–0.94 | <0.001   |
| **Current smoking (no)**      |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.88 | 0.82–0.94 | 0.013    | 0.84 | 0.79–0.91 | <0.001   |
| Per 1-SD increase             | 0.83 | 0.75–0.91 | 0.009    | 0.80 | 0.71–0.86 | <0.001   |
| **Number of drinking years (≥6)** |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.92 | 0.87–0.96 | 0.030    | 0.89 | 0.82–0.95 | 0.002    |
| Per 1-SD increase             | 0.83 | 0.78–0.90 | 0.012    | 0.80 | 0.78–0.92 | <0.001   |
| **Number of drinking years (<6)** |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.89 | 0.83–0.95 | 0.015    | 0.86 | 0.81–0.94 | <0.001   |
| Per 1-SD increase             | 0.84 | 0.77–0.91 | 0.013    | 0.81 | 0.76–0.92 | <0.001   |
| **Frequency of exercises ≥3/week (yes)** |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.90 | 0.84–0.95 | 0.012    | 0.86 | 0.78–0.91 | 0.001    |
| Per 1-SD increase             | 0.81 | 0.73–0.87 | 0.008    | 0.75 | 0.62–0.81 | <0.001   |
| **Frequency of exercises ≥3/week (no)** |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.91 | 0.84–0.97 | 0.017    | 0.87 | 0.82–0.94 | <0.001   |
| Per 1-SD increase             | 0.86 | 0.79–0.95 | 0.015    | 0.83 | 0.78–0.93 | <0.001   |
| **Heart disease (yes)**       |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.87 | 0.78–0.94 | 0.008    | 0.82 | 0.71–0.83 | <0.001   |
| Per 1-SD increase             | 0.72 | 0.61–0.83 | 0.001    | 0.70 | 0.59–0.82 | <0.001   |
| **Heart disease (no)**        |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.92 | 0.86–0.95 | 0.007    | 0.84 | 0.72–0.84 | <0.001   |
| Per 1-SD increase             | 0.81 | 0.70–0.82 | 0.018    | 0.73 | 0.67–0.80 | <0.001   |
| **Hypertension (yes)**        |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.96 | 0.90–1.19 | 0.232    | 0.92 | 0.89–1.14 | 0.092    |
| Per 1-SD increase             | 0.95 | 0.88–1.17 | 0.197    | 0.90 | 0.87–1.13 | 0.087    |
| **Hypertension (no)**         |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.65 | 0.45–0.83 | 0.005    | 0.59 | 0.40–0.76 | <0.001   |
| Per 1-SD increase             | 0.61 | 0.43–0.86 | <0.001   | 0.56 | 0.41–0.73 | <0.001   |
| **Diabetes (yes)**            |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.94 | 0.85–1.17 | 0.165    | 0.88 | 0.78–1.10 | 0.076    |
| Per 1-SD increase             | 0.90 | 0.81–1.14 | 0.088    | 0.82 | 0.71–1.03 | 0.068    |
| **Diabetes (no)**             |      |          |          |      |          |          |
| Continuous, per 1 umol/L increment | 0.68 | 0.47–0.84 | 0.008    | 0.62 | 0.42–0.78 | <0.001   |
| Per 1-SD increase             | 0.62 | 0.42–0.80 | 0.003    | 0.58 | 0.39–0.70 | <0.001   |

Adjusted for age, gender, marital status, blood analysis including hemoglobin A1c %, HOMA-IR, fasting glucose levels, fasting insulin levels, total cholesterol, triglycerides, HDL cholesterol, LDL cholesterol, creatinine and C-reactive protein.

TIA, transient ischemic attack; BMI, Body mass index; HOMA-IR, Homeostasis model assessment of insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein.

As early as 1992, it was reported that the patients with ischemic stroke with the blood retinol concentrations above 2.27 µmol/L had increased rates of recovery and decreased mortality (14). In contrast, a prospective cohort study, which enrolled 1,031 patients in Finland, with an average follow-up of 12.1 years, found that in patients with a high concentration of blood retinol ≥68 µg/dl compared with those with a low concentration of blood retinol <51 µg/dl, the risk of stroke...
was not reduced (9). However, this study only included 67 stroke events, and there were not enough samples to assess the association between blood retinol and stroke. Similarly, a nested case-control study consisting of 297 ischemic stroke cases and 297 controls, with an average follow-up of 7.3 years was conducted. The results of this study suggested that there was no association between blood retinol and the risk of ischemic stroke, but the study was only conducted in a male population (8). These previous studies, which have inconsistent results, did not include enough samples and did not explore the relationship between retinol and stroke risk in the general population. Additionally, these inconsistent results may be caused by the difference in the age-related confounding factors, such as, the populations selected, the use of medications, and varying blood biochemical examinations. Therefore, it is necessary to further study whether the increased blood retinol levels can contribute to a lower risk of stroke after excluding these limitations.

Our study found a significant inverse association between blood retinol with the risk of ever TIA/stroke and currently diagnosed stroke/TIA in the general population with a large sample. The inverse association was mainly found in the participants with BMI < 28, non-hypertension, and non-diabetes. Espe et al. reported a study that included 1,177 patients with diabetic hemodialysis with an average follow-up of 4 years. Compared with the patients with diabetic hemodialysis with blood retinol ≥111 µg/dl, the patients with blood retinol 91–111 µg/dl did not have a reduced risk of stroke, while the risk did not increase in the patients with blood retinol <74 µg/dl (15). This result is consistent with the association between blood retinol and the risk of stroke in the patients with diabetes in our study. However, the pathophysiology of the patients with diabetes was different from that of the general population. Therefore, we then conducted a stratified analysis and found that diabetes was a modifier factor in the association between blood retinol and stroke. In the patients with non-diabetes, blood retinol and stroke have a significant inverse association. One previous study has conducted a stratified analysis further to find the modifier factor between blood retinol and stroke. A total of 20,702 patients with hypertension were included in a recent China Stroke Primary Prevention Trial (CSPPT) study. The results of the study suggested a significant negative correlation between blood retinol and the first stroke (per 10-µg/dl increment; OR: 0.92; 95% CI: 0.86, 0.97) and first ischemic stroke (per 10-µg/dl increment; OR: 0.92; 95% CI: 0.86, 0.98), and homocysteine was a modifier factor for the association. However, the participants in this study were all patients with hypertension, and the results may not apply to the generality of other populations (16).

Our study was the first to thoroughly examine any possible modifiers that affect the association between blood retinol and TIA/stroke in the general people, and found that overweight, hypertension, and diabetes were the effective modifier factors. It is well known that overweight, hypertension, and diabetes were the independent and harmful risk factors for stroke (17). In-depth investigation of the mechanism of overweight, it was found that the chronic mild inflammation and altered intestinal microbes play an important role in obesity (18, 19), and adipose tissue was not only considered as an inert energy store but also secretes various adipokines (such as, leptin, adiponectin, and lipase) and cytokines (such as, tumor necrosis factor-alpha (TNF-α), interleukins (ILs), and monocyte chemotactic protein (MCP)). These adipokines and cytokines are the primary mediators of inflammation and are related to obesity-related inflammatory complications, such as insulin resistance and hypertension (20, 21), which eventually increased the risk of stroke (22–24). Interestingly, the growing evidence has shown that blood retinol has a potential protective effect on obesity, diabetes, and hypertension (25, 26). Zulet et al. reported a negative relationship between the blood retinol intake and obesity (27). Other studies have reported an inverse relationship between blood retinol and BMI in the morbidly obese subjects (28–32). Additionally, blood retinol and hypertension have a negative relationship. Multiple studies on the individuals with hypertension found that the patients with hypertension have a low blood retinol level (33, 34). Retinol acyltransferase (LRAT) is a key enzyme for converting and storing retinol in the tissues. The studies have found that the level of LRAT was negatively correlated with blood pressure, and the LRAT of the hypertension group was lower than that of the non-hypertension group (35). The metabolic syndrome (METS) refers to a group of risk factors that are highly related to metabolism. The specific classification criteria of METS are not yet unified, but it is generally believed that METS includes diabetes, dyslipidemia, obesity, and hypertension. Recently, a study on patients with METS found that the patients with METS have a significantly lower level of blood retinol than the normal control group (36). Therefore, it seems that the harmful effects of diabetes, obesity, and hypertension on stroke may be weakened by the potential protective effect of retinol. These results might also further explain our finding that a strong negative correlation between blood retinol and stroke was found in the people with non-diabetic and non-hypertensive, BMI < 28. Our results also emphasize that maintaining the higher blood retinol levels may play an important role in preventing TIA/stroke after controlling overweight, hypertension, and diabetes.

There were also some limitations in this study. First, dynamic measurement of the blood retinol levels can more accurately assess the association between blood retinol and TIA/stroke risk. In this study, the blood retinol levels of participants were only evaluated in a cross-section of time. Therefore, we were unable to assess whether the blood retinol changes have an impact on the incidence of TIA/stroke. Second, although the main potential confounding factors were controlled, the results may be affected by the unmeasured or uncertain confounding factors. Third, we did not have detailed dietary information about the source of retinol for the participants. Retinol can be obtained from the animal foods, such as milk, red meat, offal, and cheese, and can also be obtained from the plant foods, such as carrots and corn. Whether retinol obtained from different source has different effects on TIA/stroke is not clear and should be further examined in future studies. Finally,
stroke includes ischemic and hemorrhagic stroke, therefore, this study was insufficient in assessing the association between the blood retinol levels and specific subtypes of stroke. Further studies should be undertaken to investigate the prevalence of ischemic stroke/hemorrhagic stroke/TIA with the blood retinol levels.

CONCLUSIONS

Although more research is needed, our data suggested that a healthy diet, such as appropriate retinol may help to prevent TIA/stroke through the potential protective effects of retinol. Our study provided the first evidence that the increased blood retinol levels may benefit TIA/stroke in the general population and the potential protective effect of retinol on TIA/stroke might be blunted by overweight, hypertension, and diabetes.

DATA AVAILABILITY STATEMENT

Publicly available datasets were analyzed in this study. This data and diabetes. TIA/stroke might be blunted by overweight, hypertension, and diabetes.

REFERENCES

1. Feigin V, Norrving B, Sudlow C, Sacco RL. Updated criteria for population-based stroke and transient ischemic attack incidence studies for the 21st century. Stroke. (2018) 49:2248–55. doi: 10.1161/STROKEAHA.118.022161
2. Boehme AK, Esenwa C, Elkind MS. Stroke risk factors, genetics, and prevention. Circ Res. (2017) 120:472–95. doi: 10.1161/CIRCRESAHA.116.308398
3. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. (2019) 50:e344–418. doi: 10.1161/STR.0000000000000211
4. Huang Z, Liu Y, Qi G, Brand D, Zheng SG. Role of vitamin A in the immune system. J Clin Med. (2018) 7:2258. doi: 10.3390/jcm70902258
5. Hori S, Kizaki K, Ishii H, Kazama M. Retinoic acid stimulates expression of thrombomodulin, a cell surface anti-coagulant glycoprotein, on human endothelial cells. Differences between up-regulation of thrombomodulin by retinoic acid and cyclic AMP. Biochem J. (1992) 281:149–54. doi: 10.1042/bj2810149
6. Swamidas GP, Basaraba RJ, Baybutt RC. Dietary retinol inhibits inflammatory responses of rats treated with monocrotaline. J Nutr. (1999) 129:1285–90. doi: 10.1093/jn/129.7.1285
7. Chadwick CC, Shaw IJ, Winneker RC. TNF-alpha and 9-cis-retinoic acid synergistically induce ICAM-1 expression: evidence for interaction of retinoid receptors with NF-kappa B. Exp Cell Res. (1998) 239:423–9. doi: 10.1006/excr.1997.3913
8. Hak AE, Ma J, Powell CB, Campos H, Gazzano JM, Willett WC, et al. Prospective study of plasma carotenoids and tocopherols in relation to risk of ischemic stroke. Stroke. (2004) 35:1584–8. doi: 10.1161/01.STR.0000132197.67350.bd
9. Karppi J, Laukkainen JA, Sivenius J, Ronkainen K, Kurl S. Serum lycopene decreases the risk of stroke in men: a population-based follow-up study. Neurology. (2012) 79:1540–7. doi: 10.1212/WNL.0b013e318262ca66
10. Brim OG, Ryff CD, Kessler RC. The MIDUS national survey: an overview. 392. In: Brim OG, Ryff CD, Kessler RC, editors. How Healthy Are We? A National 393 Study of Well-Being at Midlife. Chicago: University of Chicago Press (2004). p. 1–36. doi: 10.7208/chicago/9780226074764.001.0001
11. Ryff C, Almeida DM, Ayanian JS, Carr DS, Cleary PD, Coe C, et al. National Survey of Midlife Development in the United States (MIDUS II), 2004-2006 ICPSR04652. Inter-university Consortium for Political and Social Research (ICPSR) (2019).
12. Dienberg LG, Seeman TE, Weinstein M, Ryff CD. Bioindicators in the MIDUS national study: protocol, measures, sample, and comparative context. J Aging Health. (2010) 22:1059–80. doi: 10.1177/0734015410374355
13. Gruenewald TL, Karlamangla AS, HSu P, Stein-Merkin S, Crandall C, Koretz B, et al. History of socioeconomic disadvantage and allostatic load in later life. Soc Sci Med. (2012) 74:75–83. doi: 10.1016/j.socscimed.2011.09.037
14. De Keyser J, De Klippel N, Merkx B, Verpaer B, Herroelen L. Serum concentrations of vitamins A and E and early outcome after ischaemic stroke. Lancet. (1992) 339:1562–5. doi: 10.1016/0140-6736(92)91830-2
15. Espe KM, Raial J, Henze A, Krane V, Schweigert FJ, Hocher B, et al. Impact of vitamin A on clinical outcomes in haemodialysis patients. Nephrol Dial Transplant. (2011) 26:4054–61. doi: 10.1093/ndt/gfl171
16. Yu Y, Zhang H, Song Y, Lin T, Zhou Z, Guo H, et al. Plasma retinol and the risk of first stroke in hypertensive adults: a nested case-control study. Am J Clin Nutr. (2019) 109:449–56. doi: 10.1093/ajcn/nqy320
17. Peters SA, Huxley RR, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet. (2014) 383:1973–80. doi: 10.1016/S0140-6736(14)60040-4
18. Turnbaugh PJ, Gordon JI. The core gut microbiome, energy balance and metabolic disease. Nat Rev Microbiol. (2011) 11:85–97. doi: 10.1038/nrmicro2921
19. Turbaugh PJ, Gordon JI. The core gut microbiome, energy balance and obesity. J Physiol. (2009) 587:4153–8. doi: 10.1113/jphysiol.2009.174136
20. Hajer GR, van Haeften TW, Visseren FL. Adipose tissue dysfunction in obesity, diabetes, and vascular diseases. Eur Heart J. (2008) 29:2959–71. doi: 10.1093/eurheartj/ehn387
21. Greenberg AS, Obin MS. Obesity and the role of adipose tissue in inflammation and metabolism. Am J Clin Nutr. (2006) 83:4615–4655. doi: 10.1093/ajcn/83.2.4615
22. Lambertsen KL, Biber K, Finsen B. Inflammatory cytokines in experimental and human stroke. J Cereb Blood Flow Metab. (2012) 32:1677–98. doi: 10.1038/jcbfm.2012.88

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Clinical Research Center (CRC) at the University of California-Los Angeles, Wisconsin, or Georgetown. The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

KH was incharge of the entire project and revised the draft of the manuscript. LG and YH analyzed the data. LG drafted the first version of the manuscript. All authors took part in the interpretation of the results and in the preparation of the final version of the manuscript.

ACKNOWLEDGMENTS

We thank all the individuals responsible for the planning and administration of the MIDUS study and making the datasets of MIDUS available on their website. We also acknowledge the reviewers and editors for viewing our work.

Frontiers in Cardiovascular Medicine | www.frontiersin.org 8 November 2021 | Volume 8 | Article 744611

Guo et al. Blood Retinol in TIA/Stroke

National 393 Study of Well-Being at Midlife. Chicago: University of Chicago Press (2004). p. 1–36. doi: 10.7208/chicago/9780226074764.001.0001

Ethics Statement

The studies involving human participants were reviewed and approved by Clinical Research Center (CRC) at the University of California-Los Angeles, Wisconsin, or Georgetown. The patients/participants provided their written informed consent to participate in this study.

Author Contributions

KH was incharge of the entire project and revised the draft of the manuscript. LG and YH analyzed the data. LG drafted the first version of the manuscript. All authors took part in the interpretation of the results and in the preparation of the final version of the manuscript.

Acknowledgments

We thank all the individuals responsible for the planning and administration of the MIDUS study and making the datasets of MIDUS available on their website. We also acknowledge the reviewers and editors for viewing our work.
23. Wu JC, Zhang X, Wang JH, Liu QW, Wang XQ, Wu ZQ, et al. Gene polymorphisms and circulating levels of the TNF-alpha are associated with ischemic stroke: a meta-analysis based on 19,873 individuals. *Int Immunopharmacol.* (2019) 75:105827. doi: 10.1016/j.intimp.2019.105827
24. Saber H, Himali JJ, Shoaamaneh A, Beiser A, Pikula A, Harris TY, et al. Serum leptin levels and the risk of stroke; the Framingham study. *Stroke.* (2015) 46:2881–5. doi: 10.1161/STROKEAHA.115.009463
25. Brun PJ, Yang KJ, Lee SA, Yuen JJ, Blaner WS. Retinoids: Potent regulators of metabolism. *Biofactors.* (2013) 39:151–63. doi: 10.1002/biof.1056
26. Meerza D, Iqbal S, Zaheer S, Naseem I. Retinoids have therapeutic action in type 2 diabetes. *Nutrition.* (2016) 32:898–903. doi: 10.1016/j.nut.2016.02.003
27. Zulet MA, Puchau B, Hermsdorff HH, Navarro C, Martinez JA. Vitamin A intake is inversely related with adiposity in healthy young adults. *J Nutr Sci Vitaminol.* (2008) 54:347–52. doi: 10.3177/jnsv.54.347
28. Aasheim ET, Hofso D, Hjelmesaeth J, Birkeland KI, Bohmer T. Vitamin status in morbidly obese patients: a cross-sectional study. *Am J Clin Nutr.* (2008) 87:362–9. doi: 10.1093/ajcn/87.2.362
29. Pereira SE, Saboya CJ, Saunders C, Ramalho A. Serum levels and liver store of retinol and their association with night blindness in individuals with class III obesity. *Obes Surg.* (2012) 22:602–8. doi: 10.1007/s11695-011-0522-y
30. Mills JP, Furr HC, Tanumihardjo SA. Retinol to retinol-binding protein (RBP) is low in obese adults due to elevated apo-RBP. *Exp Biol Med.* (2008) 233:1255–61. doi: 10.3181/0803-RM-94
31. de Souza VDSL, Valeria DVG, Ramalho RA. Association of serum concentrations of retinol and carotenoids with overweight in children and adolescents. *Nutrition.* (2007) 23:392–7. doi: 10.1016/j.nut.2007.02.009
32. Teske M, Melges AP, de Souza FL, Fonseca FL, Sarni RO. Plasma concentrations of retinol in obese children and adolescents: relationship to metabolic syndrome components. *Rev Paul Pediatr.* (2014) 32:50–4. doi: 10.1590/0034-5521-4001000009
33. Neuhausser ML, Rock CL, Eldridge AL, Kristal AR, Patterson RE, Cooper DA, et al. Serum concentrations of retinol, alpha-tocopherol and the carotenoids are influenced by diet, race and obesity in a sample of healthy adolescents. *J Nutr.* (2001) 131:2184–91. doi: 10.1093/jn/131.8.2184
34. Danquah I, Dobrucky CL, Frank LK, Henze A, Amoako YA, Bedu-Addo G, et al. Vitamin A: potential misclassification of vitamin A status among patients with type 2 diabetes and hypertension in urban Ghana. *Am J Clin Nutr.* (2015) 102:207–14. doi: 10.3945/ajcn.114.101345
35. Liang X, Chen M, Qu P, Hao G, Huang Y, Chen J, et al. The association of vitamin A and vitamin D with hypertension in children: a case-control study. *Int J Hypertens.* (2018) 2018:9295147. doi: 10.1155/2018/9295147
36. Adachi K, Mishiro T, Tanaka S, Yoshikawa H, Kinoshita Y, A. Study on the relationship between reflux esophagitis and periodontitis. *Intern Med.* (2016) 55:2523–8. doi: 10.2169/internalmedicine.55.6898

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Publisher’s Note:** All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Copyright © 2021 Guo, Huang, Wan, Shen and Hong. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.